炎症基因多态性与肺癌易感性
本研究基于β-胡萝卜素和视黄醇有效性试验的巢式病例对照研究,纳入625例肺癌病例和625例匹配对照,评估11个炎症相关基因的23个多态性与肺癌风险及生存的关联。发现IL1B启动子多态性rs16944和rs1143623的次要等位基因与肺癌风险降低相关,但基因型不影响生存。
要点
- IL1B-511C>T(rs16944)次要等位基因CT和TT与肺癌风险降低相关。
- IL1B-1464C>G(rs1143623)次要等位基因CG和CC与肺癌风险降低相关。
- 未发现炎症基因多态性与肺癌生存相关。
核心结论
- IL1B启动子多态性可能调节肺癌发生风险。
研究设计与样本
- 巢式病例对照研究,从β-胡萝卜素和视黄醇有效性试验中选取625例肺癌病例和625例匹配对照。
主要发现
- IL-1β-511C>T(rs16944)次要等位基因CT vs CC的OR=0.74(95%CI:0.58-0.94),TT vs CC的OR=0.71(95%CI:0.50-1.01),p=0.03。
- IL-1β-1464C>G(rs1143623)次要等位基因CG vs GG的OR=0.75(95%CI:0.59-0.95),CC vs GG的OR=0.69(95%CI:0.46-1.03),p=0.03。
- 基因型与肺癌生存无关。
临床怎么用
- IL1B启动子多态性可能作为肺癌风险分层参考,但尚需验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chronic inflammation has been implicated in carcinogenesis, with increasing evidence of its role in lung cancer. We aimed to evaluate the role of genetic polymorphisms in inflammation-related genes in the risk for development of lung cancer. METHODS: A nested case-control study design was used, and 625 cases and 625 well-matched controls were selected from participants in the β-Carotene and Retinol Efficacy Trial, which is a large, prospective lung cancer chemoprevention trial. The association between lung cancer incidence and survival and 23 polymorphisms descriptive of 11 inflammation-related genes (interferon gamma gene [IFNG], interleukin 10 gene [IL10], interleukin 1 alpha gene [IL1A], interleukin 1 beta gene [IL1B], interleukin 2 gene [IL2], interleukin 4 receptor gene [IL4R], interleukin 4 gene [IL4], interleukin 6 gene [IL6], prostaglandin-endoperoxide synthase 2 gene [PTGS2] (also known as COX2), transforming growth factor beta 1 gene [TGFB1], and tumor necrosis factor alpha gene [TNFA]) was evaluated. RESULTS: Of the 23 polymorphisms, two were associated with risk for lung cancer. Compared with individuals with the wild-type (CC) variant, individuals carrying the minor allele variants of the IL-1β-511C>T promoter polymorphism (rs16944) (CT and TT) had decreased odds of lung cancer (OR = 0.74, [95% confidence interval (CI): 0.58-0.94] and OR = 0.71 [95% CI: 0.50-1.01], respectively, p = 0.03). Similar results were observed for the IL-1β-1464 C>G promoter polymorphism (rs1143623), with presence of the minor variants CG and CC having decreased odds of lung cancer (OR = 0.75 [95% CI: 0.59-0.95] and OR = 0.69 [95% CI: 0.46-1.03], respectively, p = 0.03). Survival was not influenced by genotype. CONCLUSIONS: This study provides further evidence that IL1B promoter polymorphisms may modulate the risk for development of lung cancer.
引用
- Eaton KD, Romine PE, Goodman GE, et al. Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol. 2018. PMID: 29408308. doi:10.1016/j.jtho.2018.01.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。